Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial.
Cleland JGF, Kalra PA, Pellicori P, Graham FJ, Foley PWX, Squire IB, Cowburn PJ, Seed A, Clark AL, Szwejkowski B, Banerjee P, Cooke J, Francis M, Clifford P, Wong A, Petrie C, McMurray JJV, Thomson EA, Wetherall K, Robertson M, Ford I, Kalra PR; IRONMAN Study Group. Cleland JGF, et al. Eur Heart J. 2024 Apr 21;45(16):1410-1426. doi: 10.1093/eurheartj/ehae086. Eur Heart J. 2024. PMID: 38446126 Free PMC article. Clinical Trial.
The Impact of Ferric Derisomaltose on Cardiovascular and Noncardiovascular Events in Patients With Anemia, Iron Deficiency, and Heart Failure With Reduced Ejection Fraction.
Ray R, Ford I, Cleland JGF, Graham F, Ahmed FZ, Al-Mohammad A, Cowburn PJ, Critoph C, Kalra PA, Lane RE, Ludman A, Pellicori P, Petrie MC, Robertson M, Seed A, Squire I, Kalra PR; INVESTIGATORS; CLINICAL TRIALS UNIT AND DATA AND STATISTICAL CENTRE; NURSING AND ADMINISTRATIVE SUPPORT; SPONSOR SUPPORT. Ray R, et al. J Card Fail. 2023 Nov 4:S1071-9164(23)00383-4. doi: 10.1016/j.cardfail.2023.10.006. Online ahead of print. J Card Fail. 2023. PMID: 37926238 Free article.
Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial.
Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, Ahmed FZ, Al-Mohammad A, Cowburn PJ, Foley PWX, Graham FJ, Japp AG, Lane RE, Lang NN, Ludman AJ, Macdougall IC, Pellicori P, Ray R, Robertson M, Seed A, Ford I; IRONMAN Study Group. Kalra PR, et al. Lancet. 2022 Dec 17;400(10369):2199-2209. doi: 10.1016/S0140-6736(22)02083-9. Epub 2022 Nov 5. Lancet. 2022. PMID: 36347265 Free article. Clinical Trial.
Changes in concentrations of cervicovaginal immune mediators across the menstrual cycle: a systematic review and meta-analysis of individual patient data.
Hughes SM, Levy CN, Katz R, Lokken EM, Anahtar MN, Hall MB, Bradley F, Castle PE, Cortez V, Doncel GF, Fichorova R, Fidel PL Jr, Fowke KR, Francis SC, Ghosh M, Hwang LY, Jais M, Jespers V, Joag V, Kaul R, Kyongo J, Lahey T, Li H, Makinde J, McKinnon LR, Moscicki AB, Novak RM, Patel MV, Sriprasert I, Thurman AR, Yegorov S, Mugo NR, Roxby AC, Micks E, Hladik F; Consortium for Assessing Immunity Across the Menstrual Cycle. Hughes SM, et al. BMC Med. 2022 Oct 5;20(1):353. doi: 10.1186/s12916-022-02532-9. BMC Med. 2022. PMID: 36195867 Free PMC article.
18 results